A new era in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): clinical breakthroughs and challenges.

Rezdiffra (resmetirom) - Madrigal Pharma

efruxifermin (NN9062) - Novo Nordisk

Zepbound (tirzepatide) - Eli Lilly

lanifibranor (IVA337) - Inventiva, Hepalys Pharma

denifanstat (TVB-2640) - Sagimet Biosci

http://www.ncbi.nlm.nih.gov/pubmed/42741482

Dongye You; Linglong Yang; Qian Zhao; Yuanhao Long; Zhifu You

Sep 16, 2026